Hyperemesis gravidarum (HG) affects roughly 1 to 3% of pregnancies in most populations, though reported rates range from 0.3% to as high as 10.8% depending on the country and how the condition is defined. That wide range exists because there is no single universal diagnostic cutoff, and milder cases sometimes go unrecognized. The most commonly cited figure in clinical practice is around 1.1%.
To put that in perspective, ordinary morning sickness (nausea and vomiting of pregnancy) hits up to 70% of pregnant women. HG is the extreme end of that spectrum, and only a small fraction of women who feel nauseated during pregnancy will develop it.
HG vs. Morning Sickness
Morning sickness is uncomfortable but manageable for most people. Among women who report nausea and vomiting during pregnancy, about 40% rate their symptoms as mild, 46% as moderate, and 14% as severe. HG sits beyond even that severe category. It’s distinguished by weight loss greater than 5% of pre-pregnancy body weight, dehydration, and the buildup of ketones in urine, which signals the body has started breaking down fat for energy because it can’t keep food down.
Where morning sickness typically eases by 12 to 14 weeks, HG can persist well into the second trimester or, for some women, throughout the entire pregnancy. The vomiting is relentless enough to interfere with daily life, work, and nutrition in ways that standard morning sickness does not.
Who Is at Higher Risk
Several factors increase the likelihood of developing HG. Younger pregnant women, particularly those under 20, appear to be at roughly three times greater risk compared to women over 35. Having experienced HG in a previous pregnancy is one of the strongest predictors. A family history of HG also raises risk, suggesting a significant genetic component.
A 2023 study published in Nature identified a key piece of that genetic puzzle. A hormone called GDF15, produced by the placenta during pregnancy, triggers nausea by acting on a specific receptor in the brain. Women who naturally have low levels of GDF15 before pregnancy appear more sensitive to the sudden surge that comes once the placenta starts producing it. The effect works like a tolerance system: women whose bodies are already accustomed to higher baseline levels of this hormone experience less severe nausea. Women with the blood disorder beta-thalassemia, for example, have chronically elevated GDF15 and report very low levels of pregnancy nausea.
Other associated risk factors include carrying multiples, unplanned pregnancy, and a recent history of miscarriage. Rates also vary across ethnic and geographic populations, though it’s difficult to separate genetic susceptibility from differences in healthcare access and reporting.
How It Affects Pregnancy Outcomes
When HG is recognized and treated, most pregnancies result in healthy babies. But the condition does carry measurable effects. In one prospective study comparing 45 HG pregnancies to 306 controls, babies born to women with HG had lower average birth weight (3.23 kg vs. 3.52 kg) and were born slightly earlier (38.4 weeks vs. 39.7 weeks). These babies also had longer hospital stays after delivery.
The more significant concern is what happens when HG goes undertreated. Prolonged dehydration, electrolyte imbalances, and severe caloric deficit can become dangerous for both the mother and baby. The condition also takes a serious psychological toll. Many women with HG report feelings of isolation, depression, and in severe cases, consideration of terminating an otherwise wanted pregnancy simply because the illness is unbearable.
Hospitalization Rates
HG remains one of the most common reasons pregnant women end up in the emergency department. Between 2006 and 2014, U.S. emergency visits for HG increased by 28%, and associated costs rose by 110%. During that same period, HG ranked as the third or fourth most common reason for hospital admission among pregnant patients.
Interestingly, while ER visits climbed, actual hospital admissions from those visits dropped by 42%, from 7.7% of ER visits in 2006 to 4.5% in 2014. This likely reflects a shift toward treating more cases with outpatient IV fluids and anti-nausea medications rather than keeping women overnight. More women are seeking emergency care, but fewer are being admitted, which suggests the condition is being managed more aggressively in outpatient settings.
Recurrence in Later Pregnancies
If you’ve had HG once, the chance of experiencing it again is substantial. A systematic review of five studies found recurrence rates ranging from 15% to 81%. That’s a wide spread, partly because the studies used different definitions and followed different populations, but the takeaway is consistent: having HG in one pregnancy is the single strongest predictor of having it in the next. Some women experience it at similar severity, while others find it milder or more severe the second time around. There is no reliable way to predict which outcome you’ll have, though the GDF15 research may eventually lead to pre-pregnancy screening tools.
Getting It Recognized
One of the biggest challenges with HG is that it’s often dismissed as “just bad morning sickness.” Women frequently report being told to try ginger or crackers long past the point where those remedies could make any difference. If you’re losing weight, unable to keep fluids down for 12 or more hours, or feel dizzy and lightheaded, those are signs that what you’re experiencing has crossed beyond normal pregnancy nausea. Urine ketone levels and basic blood work can confirm whether dehydration and nutritional depletion have set in.
Treatment typically involves IV fluids to correct dehydration, anti-nausea medications, and in some cases, nutritional support. The goal is to break the cycle of vomiting and dehydration early, before it compounds. Women who receive treatment sooner generally have shorter and less severe episodes than those who try to push through without help.